Clinical Trial

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

Study acronym: TARGET-IBD
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Protocol Amendment History 85 amendments
This ClinicalTrials.gov record has been amended 85 times since 2017-08-11; most recent amendment 2026-03-16.
Status change: Recruiting → Active, Not Recruiting 2025-11-20
Trial Details
NCT Number NCT03251118
Lead Sponsor Target PharmaSolutions, Inc.
Conditions Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Enrollment 15,000 participants
Start Date 2017-07-24
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-17